2025/08/05 by Sanjay M. Sisodiya, Simona Balestrini, Samuel F. Berkovic +10 · 1 voice · 1 citation
Medicine · #Epilepsy research and treatment #Infectious Encephalopathies and Encephalitis #Neonatal and fetal brain pathology
paper · doi:10.1111/epi.18582
openalex publication_date 2025/08/05 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
S.M.S. has received honoraria for educational events or advisory boards from Jazz Pharma, Angelini Pharma, Biocodex, Eisai, and Zogenix/UCB; institutional contributions for advisory boards, educational events, or consultancy work from Eisai, Jazz/GW Pharma, Servier, Stoke Therapeutics, Takeda, UCB, and Zogenix; and serves on the scientific advisory board for Dravet Syndrome UK. S.B. has served on scientific advisory boards for Biocodex and Longboard Pharmaceuticals and has received speaker honoraria from Angelini, Biocodex, Eisai, Lusofarmaco, and Jazz Pharma. S.F.B. was supported by National Health and Medical Research Council (NHMRC) (grants 1091593; 1196637); received industry support from educational activities from UCB Pharma, Eisai, SEER, Chiesi, and LivaNova; received renumeration from Praxis Precision Medicines, Sequiris, Eisai, DeltaMed, and the Epilepsy Foundation; and may accrue further revenue on a patent for SCN1A testing held by Bionomics Inc.; and licensed to various diagnostic companies. L.M.C. has received educational support and honoraria from UCB. J.H.C. has received research grants from Zogenix (now a part of UCB), Marinus, GW Pharma (now Jazz Pharmaceuticals), Vitaflo, Longboard (now Lundbeck), Stoke Therapeutics, Ultragenyx, UCB, National Institute of Health Research (NIHR), EPSRC, GOSH Charity, ERUK, the Waterloo Foundation, and the Great Ormond Street Hospital NIHR Biomedical Research Centre; and has served as consultant/advisor for UCB, GW Pharma (now Jazz Pharmaceuticals), Longboard (Lundbeck), and Biocodex, for which remuneration was made to the department, outside of the submitted work; serves as Chair of the Medical Board for DravetUK, Hope for Hypothalamic Hamartoma, and Matthews Friends; and endowed chair at UCL Great Ormond Street Institute of Child Health. C.E. and G.W. report that Dravet Syndrome UK has received support from and/or has served as paid consultant for Biocodex, Encoded Therapeutics, Lundbeck, Jazz Pharmaceuticals, Stoke Therapeutics, Takeda, and UCB. R.N. has received consulting and speaking fees from Nutricia, Zogenix, Advicenne, Eisai, Jazz and GW Pharmaceuticals, Neuraxpharma, Stoke, Newbridge pharmaceuticals, UCB, and Biocodex; consulting fees from Takeda, Biogen, Supernus, Orion, Atalanta therapeutics, and Servier; served as principal investigator on clinical trials for Zogenix, Eisai, UCB, Biocodex Nutricia and Jazz pharmaceuticals; and has received grants from EU FP7 program, Horizons 2020 Program, European joint program on rare diseases program (EJP-RD), ERDERA partnership on rare diseases (EU), Imagine Institute Program and Bettencourt Schueller Foundation, Realised IHI EU project, FAMA Philatropic fund supporting the GEEN-DS chair at institute Imagine and France 2030 RHU program Innov-4ePiK, and MEDITWIN project. A.S. received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Longboard, Neuraxpahrm, Stoke Therapeutics, Takeda, UCB Pharma, and UNEEG Medical. I.E.S. has served on scientific advisory boards for BioMarin, Cerecin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Longboard Pharmaceuticals, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, and Xenon Pharmaceuticals; has received speaker honoraria from Akumentis, BioMarin, Biocodex, Chiesi, Eisai, GlaxoSmithKline, Liva Nova, Nutricia, Stoke Therapeutics, UCB, and Zuellig Pharma; has received funding for travel from Biocodex, Biomarin, Encoded Therapeutics, Eisai, GlaxoSmithKline, Stoke Therapeutics, and UCB; has served as an investigator for Anavex Life Sciences, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc., Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, SK Life Science, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix, and Zynerba; has consulted for Atheneum Partners, Biohaven Pharmaceuticals, BioMarin, Care Beyond Diagnosis, Encoded Therapeutics, Epilepsy Consortium, Ovid Therapeutics, UCB, and Zynerba Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd. and a Director of the Australian Academy of Health and Medical Sciences and the Royal Society (Australia). She may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics Inc. and licensed to various diagnostic companies; and has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). The other authors declare no conflict of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.